CAS 135-09-1|hydroflumethiazide
| Common Name | hydroflumethiazide | ||
|---|---|---|---|
| CAS Number | 135-09-1 | Molecular Weight | 331.29200 |
| Density | 1.678g/cm3 | Boiling Point | 531.6ºC at 760 mmHg |
| Molecular Formula | C8H8F3N3O4S2 | Melting Point | 272-273ºC |
| MSDS | ChineseUSA | Flash Point | 275.3ºC |
| Symbol | GHS08 | Signal Word | Danger |
Names
| Name | 1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1λ6,2,4-benzothiadiazine-7-sulfonamide |
|---|---|
| Synonym | More Synonyms |
hydroflumethiazide BiologicalActivity
| Description | Hydroflumethiazide (Methforylthiazidine) is an orally active and potent thiazide diuretic. Hydroflumethiazide possesses the ability to directly stimulate A cell secretion in the normal and alloxan diabetic pancreas[1][2][3]. |
|---|---|
| Related Catalog | Research Areas >>EndocrinologySignaling Pathways >>Others >>OthersResearch Areas >>Metabolic Disease |
| References | [1]. Selvaag E, et al. Phototoxicity to sulphonamide derived oral antidiabetics and diuretics. Comparative in vitro and in vivo investigations. In Vivo. 1997 Jan-Feb;11(1):103-7. [2]. Brørs O, et al. Pharmacokinetics of a single oral dose of hydroflumethiazide in health and in cardiac failure.-. Eur J Clin Pharmacol. 1978 Nov 9;14(1):29-37. [3]. Hermansen K, et al. Effects of a thiazide diuretic (hydroflumethiazide) and a loop diuretic (bumetanide) on the endocrine pancreas: studies in vitro. Metabolism. 1985 Aug;34(8):784-9. |
Chemical & Physical Properties
| Density | 1.678g/cm3 |
|---|---|
| Boiling Point | 531.6ºC at 760 mmHg |
| Melting Point | 272-273ºC |
| Molecular Formula | C8H8F3N3O4S2 |
| Molecular Weight | 331.29200 |
| Flash Point | 275.3ºC |
| Exact Mass | 330.99100 |
| PSA | 135.12000 |
| LogP | 3.34280 |
| Vapour Pressure | 2.2E-11mmHg at 25°C |
| Index of Refraction | 1.55 |
| InChIKey | DMDGGSIALPNSEE-UHFFFAOYSA-N |
| SMILES | NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NCNS2(=O)=O |
| Storage condition | Refrigerator |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- >10 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,629,1982
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 6280 mg/kg
- TOXIC EFFECTS :
- Peripheral Nerve and Sensation - spastic paralysis with or without sensory change Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - other changes
- REFERENCE :
- JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 134,273,1961
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 750 mg/kg
- TOXIC EFFECTS :
- Peripheral Nerve and Sensation - spastic paralysis with or without sensory change Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - other changes
- REFERENCE :
- JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 134,273,1961
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Parenteral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 1182 mg/kg
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold
- REFERENCE :
- FMXXAJ French Medicament Patent Document. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231) Discontinued. Volume(issue)/page/year: #80M
Safety Information
| Symbol | GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H317-H334 |
| Precautionary Statements | P261-P280-P284-P304 + P340-P342 + P311 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
| Hazard Codes | Xn,Xi |
| Risk Phrases | R42/43 |
| Safety Phrases | S36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 2 |
| RTECS | DK9625000 |
| HS Code | 2935009090 |
Customs
| HS Code | 2935009090 |
|---|---|
| Summary | 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0% |
Articles25
More Articles| Do thiazides reduce intestinal oxalate absorption?: a study in vitro using rabbit colon. Clin. Sci. 86(3) , 353-7, (1994) 1. The purpose of the present study was to examine the effects of various diuretics on intestinal oxalate transport. Transmural oxalate fluxes were measured across isolated, short-circuited tissue seg... | |
| Comparative effects of LN 5330 and diazoxide on insulin release and 86Rb+ permeability in perifused rat islets of Langerhans. Biochem. Pharmacol. 42(4) , 787-91, (1991) The benzothiadiazine derivative LN 5330 (chloro-7 trifluoromethyl-6 benzothiadiazine-1,2,4-dioxide-1,1) has been shown to inhibit insulin secretion and calcium uptake. The present study was carried ou... | |
| Metabolic effects of propranolol and hydroflumethiazide treatment in Kenyans with mild to moderate essential hypertension. East Afr. Med. J. 70(11) , 696-700, (1993) In a prospective single-blind comparative trial, sixty newly diagnosed mild to moderate hypertensives were randomly assigned to either propranolol or hydroflumethiazide monotherapy. Baseline fasting s... |
Synonyms
| EINECS 205-173-8 |
| Robezon |
| Spandiuril |
| Saluron |
| MFCD00057316 |
| hydroflumethyazide |
| Glomerulin |
| hydroflumenthiazide |
| Diurometon |
| hydroflumethiazide |
| Flutizide |
| Hidroflumetiazid |
| Diuredemina |
| Hidroalogen |
